Novartis restructures its development strategy

Novartis CEO Daniel Vasella (photo) tells the Wall Street Journal that he knew Novartis had become too big and too bureaucratic when one of the company's top scientists expressed delight at finally meeting him. So he's set out to reconstruct the drug giant he built, with a particular emphasis on drug discovery.  

At the top of the pipeline: two meningitis vaccines that could become blockbusters. And the new pharma chief--Joe Jimenez--is breaking up investigators into small teams so they can go one on one with regulators to see if they should move ahead with a development program.

- read the article from the Wall Street Journal

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.